Understanding HIV resistance, fitness, replication capacity and compensation: Targeting viral fitness as a therapeutic strategy

Expert Opinion on Investigational Drugs

Volumn 13, Issue 8, 2004, Pages 933-958

  Buckheit Jr , Robert W ^a  

^a ImQuest Biosciences   (United States)

Author keywords

Antiviral; Capacity; Compensation; Fitness; Fusion inhibitor; HAART; HIV; Non nucleoside RT inhibitor; Nucleoside RT inhibitor; Protease inhibitor; Replication; Resistance; Therapy

Indexed keywords

1 (3 CYCLOPENTENYLMETHYL) 6 (3,5 DIMETHYLBENZOYL) 5 ETHYLURACIL; ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CALANOLIDE A; COSTATOLIDE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NELFINAVIR; NEVIRAPINE; NSC 661122; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; UC 10; UC 84; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; CELL CULTURE; CODON; CONCENTRATION (PARAMETERS); DRUG CLASSIFICATION; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MOLECULAR MECHANICS; PROTEIN PHOSPHORYLATION; REVIEW; VIROGENESIS; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HIV; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 4344653867     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.8.933     Document Type: Review

References (221)

1. SCHOOLEY RT: Antiretroviral chemotherapy. In: AIDS and Other Manifestations of HIV Infection. GP Wormser (Ed.), Elsevier Academic Press, San Diego, USA (2004):841-854.
2. DE CLERCQ E: Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. (1995) 8:200-239.
3. MORSE GD, SHELTON MJ, O'DONNELL AM: Comparative pharmacokinetics of antiviral nucleoside analogues. Clin. Pharmacokinet. (1993) 24:101-123.
4. EMINI EA, BYRNES VW, CONDRA JH et al.: The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors. Arch. Virol. Suppl. (1994) 9:11-17.
5. MELLORS J, LARDER B, SCHINAZI R: Mutation in HIV-1 reverse transcriptase and protease associated with drug resistance. Int. Antiviral News (1995) 3:8-15.
6. DE CLERCQ E: New developments in the chemotherapy of lentivirus (human immunodeficiency virus) infections: sensitivity/resistance of HIV-1 to nonnucleoside HIV-1-specific inhibitors. Ann. NY Acad. Sci. (1994) 724:438-456.
7. KOHL NE, EMINI EA, SCHLEIF WA et al.: Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA (1988) 85:4686-4690.
8. CRAIG J, GREIF C, MILLS J: Anti-HIV activity of a specific inhibitor of HIV proteinase Ro318959 on virus maturation in a chronically infected promonocytic cell line. Antivir. Chem. Chemother. (1991) 2:188-196.
9. WILD C, GREENWELL T, MATTHEWS T: A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses (1993) 9:1051-1053.
10. WILD CT SHUGARS DC, GREENWELL TK et al.: Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus Type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA (1994) 91:9770-9774.
11. DE CLERCQ E: New developments in anti-HIV chemotherapy. Curr. Med. Chem. (2001) 8:1543-1572.
12. HAZUDA DJ, FELOCK P, WITMER M et al.: Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (2000) 287:646-650.
13. OJWANG JO, BUCKHEIT RW, POMMIER Y et al.: T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus Type 1. Antimicrob. Agents Chemother. (1995) 39:2426-2435.
14. PANNECOUQUE C, PLUYMERS W, VAN MAELE B et al.: New class of HIV integrase inhibitors that block viral replication in cell culture. Curr. Biol. (2002) 12:1169-1177.
15. POMMIER Y. NEAMATI N: Inhibitors of human immunodeficiency virus integrase. Adv. Virus Res. (1999) 52:427-458.
16. ROBINSON WE Jr, CORDEIRO M, ABDEL-MALEK S et al.: Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase. Mol. Pharmacol. (1996) 50:846-855.
17. GARVEY E, ROMINES K, BOONE L: Discovery and Development of New HIV Medicines. In: AIDS and Other Manifestations of HIV Infection. GP Wormser (Ed.), Elsevier, San Diego, USA (2004):855-866.
18. TURPIN J A, SONG Y, INMAN JK et al.: Synthesis and biological properties of novel pyridinioalkanoyl thiolesters (PATE) as anti-HIV-1 agents that target the viral nucleocapsid protein zinc fingers. J. Med. Chem. (1999) 42:67-86.
19. TURPIN JA, TERPENING SJ, SCHAEFFER CA et al.: Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles. J. Virol. (1996) 70:6180-6189.
20. RICE WG, BAKER DC, SCHAEFFER CA et al.: Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob. Agents Chemother. (1997) 41:419-426.
21. RICE WG, TURPIN JA, SCHAEFFER CA et al.: Evaluation of selected chemotypes in coupled cellular and molecular target-based screens identifies novel HIV-1 zinc finger inhibitors. J. Med. Chem. (1996) 39:3606-3616.
22. RICE WG, TURPIN JA, HUANG M et al.: Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nat. Med. (1997) 3:341-345.
23. DEEKS SG: International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. (2001) 26(Suppl. 1):S25-S33.
24. MILLER V: International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J. Acquir. Immune Defic. Syndr. (2001) 26(Suppl. 1):S34-S50.
25. LOVEDAY C: International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance J. Acquir. Immune Defic. Syndr. (2001) 26(Suppl. 1):S10-S24.
26. WAINBERG MA. HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors J. Acquir. Immune Defic. Syndr. (2003) 34(Suppl. 1):S2-S7.
27. DE JONG MD, SCHUURMAN R, LANGE JM et al.: Replication of a preexisting resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure. Antivir. Ther. (1996) 1:33-41.
28. BALOTTA C, BERLUSCONI A, PAN A et al.: Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and preexisting mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antivir. Ther. (2000) 5:7-14.
29. SHI C, MELLORS JW: A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob. Agents Chemother. (1997) 41:2781-2785.
30. STRAIR RK, MEDINA DJ, NELSON CJ et al.: Recombinant retroviral systems for the analysis of drug resistant HIV. Nucleic Acids Res. (1993) 21:4836-4842.
31. HAVLIR DV, EASTMAN S, GAMST A et al.: Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J. Virol. (1996) 70:7894-7899.
32. MALLON P. COOPER D, CARR A: Toxicities of antiretroviral therapies. In: AIDS and Other Manifestations of HIV Infection. G Wormser (Ed.), Elsevier Academic Press, San Diego, USA (2004):867-882.
33. QUINONES-MATEU ME, ARTS EJ: Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist. Updat. (2002) 5:224-233.
34. SUFKA SA, FERRARI G, GRYSZOWKA VE et al.: Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. J. Infect. Dis. (2003) 187:1027-1037.
35. GOTTE M, ARION D, PARNIAK MA et al.: The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J. Virol. (2000) 74:3579-3585.
36. BOYER PL, SARAFIANOS SG, ARNOLD E et al.: The M184V mutation reduces the selective excision of zidovudine 5′-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. J. Virol. (2002) 76:3248-3256.
37. DEVAL J, WHITE K L, MILLER MD et al.: Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J. Biol. Chem. (2004) 279:509-516.
38. WATKINS T, RESCH W, IRLBECK D et al.: Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. (2003) 47:759-769.
39. BUCKHEIT RW: Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection. Expert Opin. Investig. Drugs (2001) 10:1423-1442.
40. BUCKHEIT RW Jr, FLIAKAS-BOLTZ V, DECKER WD et al.: Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antiviral Res. (1995) 26:117-132.
41. BUCKHEIT RW Jr, FLIAKAS-BOLTZ V, YEAGY-BARGO S et al.: Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase. Virology (1995) 210:186-193.
42. BUCKHEIT RW Jr, HOLLINGSHEAD MG, GERMANY-DECKER J et al.: Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor. Antiviral Res. (1993) 21:247-265.
43. BUCKHEIT RW Jr, KINJERSKI TL, FLIAKAS-BOLTZ V et al.: Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide. Antimicrob. Agents Chemother. (1995) 39:2718-2727.
44. BUCKHEIT RW Jr, SNOW MJ, FLIAKAS-BOLTZ V et al.: Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates. Antimicrob. Agents Chemother. (1997) 41:831-837.
45. BUCKHEIT RW Jr, WATSON K, FLIAKAS-BOLTZ V et al.: SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob. Agents Chemother. (2001) 45:393-400.
46. BUCKHEIT RW Jr, WHITE EL, FLIAKAS-BOLTZ V et al.: Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrob. Agents Chemother. (1999) 43:1827-1834.
47. KINJERSKI TL, BUCKHEIT RW Jr: The role of genotypic heterogeneity in wild type virus populations on the selection of nonnucleoside reverse transcriptase inhibitor-resistant viruses. Antiviral Res. (1997) 33:109-115.
48. BALZARINI J, KARLSSON A, DE CLERCQ E: Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives. Mol. Pharmacol. (1993) 44:694-701.
49. BALZARINI J, KARLSSON A, PEREZ-PEREZ MJ et al.: Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology (1993) 196:576-585.
50. BALZARINI J, JONCKHEERE H, HARRISON WA et al.: Oxathiin carboxanilide derivatives: a class of nonnucleoside HIV-1 specific reverse transcriptase inhibitors (NNRTIs) that are active against mutant HIV-1 strains resistant to other NNRTIs. Antiviral Chem. Chemother. (1995) 6:169-178.
51. BALZARINI J, PEREZ-PEREZ MJ, VELAZQUEZ S et al.: Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives). Proc. Natl. Acad. Sci. USA (1995) 92:5470-5474.
52. BUCKHEIT RW, RUSSELL J, HARTMAN T et al.: Synergistic anti-HIV acivity of zinc-finger inhibitory molecules used in combination with a variety of other anti-HIV agents. 17th International Conference on Antiviral Research. Tucson, AZ, USA (2004).
53. PARSLEY T, HARTMAN T, BRENNER T et al.: Inhibition of Late Stage Events in HIV Replication: Therapeutic Compounds with Effects on Viral RNA Synthesis. 17th International Conference on Antiviral Research. Tucson, AZ, USA (2004).
54. PARIKH U, CALEF C, LARDER B et al.: HIV Sequence Compendium 2002. S Wolinksy (Ed.), Theoretical Biology And Biophysics Group, Los Alamos, USA (20002):95-183.
55. DEEKS SG, WRIN T, LIEGLER T et al.: Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. (2001) 344:472-480.
56. IZOPET J, SOUYRIS C, HANCE A et al.: Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J. Infect. Dis. (2002) 185:1506-1510.
57. MILLER V, SABIN C, HERTOGS K et al.: Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS (2000) 14:2857-2867.
58. KIJAK GH, SIMON V, BALFE P et al.: Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure. J. Virol. (2002) 76:7000-7009.
59. JOLY V, DESCAMPS D, PEYTAVIN G et al.: Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs. Antimicrob. Agents Chemother. (2004) 48:172-175.
60. BLOWER SM, ASCHENBACH AN, GERSHENGORN HB et al.: Predicting the unpredictable: transmission of drug-resistant HIV. Nat. Med. (2001) 7:1016-1020.
61. LEIGH BROWN AJ, FROST SD, MATHEWS WC et al.: Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J. Infect. Dis. (2003) 187:683-686.
62. PHILLIPS AN, YOULE M, JOHNSON M et al.: Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development. AIDS (2001) 15:2211-2220.
63. RIBEIRO RM, BONHOEFFER S, NOWAK MA: The frequency of resistant mutant virus before antiviral therapy. AIDS (1998) 12:461-465.
64. SIMON V, VANDERHOEVEN J, HURLEY A et al.: Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS (2002) 16:1511-1519.
65. SELMI B, DEVAL J, BORETTO J et al.: Nucleotide analogue binding, catalysis and primer unblocking in the mechanisms of HIV-1 reverse transcriptase-mediated resistance to nucleoside analogues. Antivir. Ther. (2003) 8:143-154.
66. KREBS R, IMMENDORFER U, THRALL SH et al.: Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC. Biochemistry (1997) 36:10292-10300.
67. FENG JY, ANDERSON KS: Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry (1999) 38:9440-9448.
68. SELMI B, BORETTO J, SARFATI SR et al.: Mechanism-based suppression of dideoxynucleotide resistance by K65R human immunodeficiency virus reverse transcriptase using an alpha-boranophosphate nucleoside analogue. J. Biol. Chem. (2001) 276:48466-48472.
69. MEYER PR, MATSUURA SE, MIAN AM et al.: A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell (1999) 4:35-43.
70. MEYER PR, MATSUURA SE, SCHINAZI RF et al.: Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates. Antimicrob. Agents Chemother. (2000) 44:3465-3472.
71. BOYER PL, SARAFIANOS SG, ARNOLD E et al.: Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. J. Virol. (2002) 76:9143-9151.
72. MAS A, VAZQUEZ-ALVAREZ BM, DOMINGO E et al.: Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. J. Mol. Biol. (2002) 323:181-197.
73. NAEGER LK, MARGOT NA, MILLER MD: ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. (2002) 46:2179-2184.
74. MATAMOROS T, FRANCO S, VAZQUEZ-ALVAREZ BM et al.: Molecular determinants of multi-nucleoside analogue resistance in HIV-1 reverse transcriptases containing a dipeptide insertion in the fingers subdomain: effect of mutations D67N and T215Y on removal of thymidine nucleotide analogues from blocked DNA primers. J. Biol. Chem. (2004) 279:24569-24577.
75. SPENCE RA, KATI WM, ANDERSON KS et al.: Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science (1995) 267:988-993.
76. RITTINGER K, DIVITA G, GOODY RS: Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors Proc. Natl. Acad. Sci. USA (1995) 92:8046-8049.
77. GU Z, GAO Q, FAUST EA et al.: Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC. J. Gen. Virol. (1995) 76(Pt 10):2601-2605.
78. DESCAMPS D, COLLIN G, LETOURNEUR F et al.: Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J. Virol. (1997) 71:8893-8898.
79. HIZI A, TAL R, SHAHARABANY M et al.: Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob. Agents Chemother. (1993) 37:1037-1042.
80. SHIH CK, ROSE JM, HANSEN GL et al.: Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. Proc. Natl. Acad. Sci. USA (1991) 88:9878-9882.
81. YANG G, SONG Q, CHARLES M et al.: Use of chimeric human immunodeficiency virus types 1 and 2 reverse transcriptases for structure-function analysis and for mapping susceptibility to nonnucleoside inhibitors. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1996) 11:326-333.
82. QUINONES-MATEU ME, SORIANO V, DOMINGO E et al.: Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate. Virology (1997) 236:364-373.
83. JOHNSON VA, BRUN-VEZINET F, CLOTET B et al.: Drug resistance mutations in HIV-1. Top. HIV Med. (2003) 11:215-221.
84. MERVIS RJ, AHMAD N, LILLEHOJ EP et al.: The Gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors. J. Virol. (1988) 62:3993-4002.
85. PENG C, HO BK, CHANG TW et al.: Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J. Virol. (1989) 63:2550-2556.
86. CONDRA JH, HOLDER DJ, SCHLEIF WA et al.: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. (1996) 70:8270-8276.
87. ERICKSON JW: The not-so-great escape. Nat. Struct. Biol. (1995) 2:523-529.
88. MOLLA A, KORNEYEVA M, GAO Q et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. (1996) 2:760-766.
89. RICHMAN DD: HIV chemotherapy. Nature (2001) 410:995-1001.
90. KEMPF DJ, ISAACSON JD, KING MS et al.: Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. (2001) 75:7462-7469.
91. SEIBERT SA, HOWELL CY, HUGHES MK et al.: Natural selection on the gag, pol, and env genes of human immunodeficiency virus 1 (HIV-1). Mol. Biol. Evol. (1995) 12:803-813.
92. SUZUKI Y, GOJOBORI T: A method for detecting positive selection at single amino acid sites. Mol. Biol. Evol. (1999) 16:1315-1328.
93. WU TD, SCHIFFER CA, GONZALES MJ et al.: Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J. Virol. (2003) 77:4836-4847.
94. SHAFER RW, DUPNIK K, WINTERS M et al.: A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. In: HIV Sequence Compendium 2001. S Wolinksy (Ed.), Theoretical Biology and Biophysics Group, Los Alamos, USA (2001).
95. DAUBER DS, ZIERMANN R, PARKIN N et al.: Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease. J. Virol. (2002) 76:1359-1368.
96. DOYON L, CROTEAU G, THIBEAULT D et al.: Second focus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. (1996) 70:3763-3769.
97. FEHER A, WEBER IT, BAGOSSI P et al.: Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. Eur. J. Biochem. (2002) 269:4114-4120.
98. KAUFMANN GR, SUZUKI K, CUNNINGHAM P et al.: Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs. AIDS Res. Hum. Retroviruses (2001) 17:487-497.
99. ZHANG YM, IMAMICHI H, IMAMICHI T et al.: Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. (1997) 71:6662-6670.
100. WEI X, DECKER JM, LIU H et al.: Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. (2002) 46:1896-1905.
101. LU J, SISTA P, GIGUEL F et al.: Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J. Virol. (2004) 78:4628-4637.
102. RIMSKY LT, SHUGARS DC, MATTHEWS TJ: Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. (1998) 72:986-993.
103. LABROSSE B, LABERNARDIERE JL, DAM E et al.: Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J. Virol. (2003) 77:1610-1613.
104. KING PJ, ROBINSON WE Jr: Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase J. Virol. (1998) 72:8420-8424.
105. FIKKERTV, VAN MAELE B, VERCAMMEN J et al.: Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J. Virol. (2003) 77:11459-11470.
106. YOSHINAGA AS, T F et al.: IX Conference on Retroviruses and Opportunistic Injections. Brasília, Brazil (2002).
107. NAKAJIMA N, LU R, ENGELMAN A: Human immunodeficiency virus type 1 replication in the absence of integrase-mediated DNA recombination: definition of permissive and nonpermissive T-cell lines. J. Virol. (2001) 75:7944-7955.
108. SPIRA S, WAINBERG MA, LOEMBA H et al.: Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J. Antimicrob. Chemother. (2003) 51:229-240.
109. RENJIFO B: HIV-1 subtypes and Recombinants. In: AIDS in Africa. S Tlou (Ed.), Kluwer Academic/Plenum Publishers, New York, USA (2002):138-157.
110. SIMON F, MAUCLERE P, ROQUES P et al.: Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat. Med. (1998) 4:1032-1037.
111. QUINONES-MATEU M, ARTS E: Recombination in HIV-1: update and implications. AIDS Reviews (1999) 1:89-100.
112. TRIQUES K, BOURGEOIS A, VIDAL N et al.: Near-full-length genome sequencing of divergent African HIV type 1 subtype F viruses leads to the identification of a new HIV type 1 subtype designated K. AIDS Res. Hum. Retroviruses (2000) 16:139-151.
113. PIOT P, BARTOS M: The epidemiology of HIV and AIDS. In: AIDS in Africa. S Tlou (Ed.), Kluwer Academic/Plenum Publishers, New York, USA (2002):200-217.
114. JANSSENS W, BUVE A, NKENGASONG JN: The puzzle of HIV-1 subtypes in Africa. AIDS (1997) 11:705-712.
115. GURTLER LG, HAUSER PH, EBERLE J et al.: A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J. Virol. (1994) 68:1581-1585.
116. GAO F. YUE L, ROBERTSON DL et al.: Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J. Virol. (1994) 68:7433-7447.
117. CARIDE E, HERTOGS K, LARDER B et al.: Genotyping and phenotyping analysis of B and non-B HIV-1 subtypes from Brazilian patients under HAART. Antivir. Ther. (2000) 3(Suppl.):128.
118. PILLAY D, SINKA K, RICE P et al.: Impact of HIV-1 subtype on NNRTI resistance mutations. Antivir. Ther. (2000) 3(Suppl.):128.
119. QUINONES-MATEU ME, ALBRIGHT JL, MAS A et al.: Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1. J. Virol. (1998) 72:9002-9015.
120. DESCAMPS D, COLLIN G, LOUSSERT-AJAKA I et al.: HIV-1 group O sensitivity to antiretroviral drugs. AIDS (1995) 9:977-978.
121. TANTILLO C, DING J, JACOBO-MOLINA A et al.: Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. (1994) 243:369-387.
122. APETREI C, DESCAMPS D, COLLIN G et al.: Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. J. Virol. (1998) 72:3534-3538.
123. LOEMBA H, BRENNER B, PARNIAK MA et al.: Co-receptor usage and HIV-1 intra-dade C polymorphisms in the protease and reverse transcriptase genes of HIV-1 isolates from Ethiopia and Botswana. Antivir. Ther. (2002) 7:141-148.
124. LOEMBA H, BRENNER B, PARNIAK MA et al.: Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. Antiviral Res. (2002) 56:129-142.
125. LOEMBA H, BRENNER B, PARNIAK MA et al.: Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob. Agents Chemother. (2002) 46:2087-2094.
126. PALMER S, ALAEUS A, ALBERT J et al.: Drug susceptibility of subtypes AB,C,D, and E human immunodeficiency virus type 1 primary isolates. AIDS Res. Hum. Retroviruses (1998) 14:157-162.
127. PILLAY D, WALKER A S, GIBB DM et al.: Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J. Infect. Dis. (2002) 186:617-625.
128. HARTMAN T: Sensitive methodology to assess replication, fitness, replication capacity and compensatory mutations of reverse transcriptase inhibitor resistant virus. 17th International Conference on Antiviral Research. Tucson, AZ, USA (2004).
129. WATSON K. Selection and characterization of virus strains resistant to a novel pyrimidinedione nonnucleoside inhibitor of HIV-1 and HIV-2. 17th International Conference on Antiviral Research. Tucson, AZ, USA (2004).
130. CLAVEL F, RACE E, MAMMANO F: HIV drug resistance and viral fitness. Adv. Pharmacol. (2000) 49:41-66.
131. NIJHUIS M, DEEKS S, BOUCHER C: Implications of antiretroviral resistance on viral fitness. Curr. Opin. Infect. Dis. (2001) 14:23-28.
132. QUINONES-MATEU ME, ARTS EJ: HIV-1 fitness: implications for drug resistance, disease progression, and global epidemic evolution. In: HIV Sequence Compendium 2001. Theoretical Biology And Biophysics Group, Los Alamos, USA.
133. BATES M, WRIN T, HUANG W et al.: Practical applications of viral fitness in clinical practice. Curr. Opin. Infect. Dis. (2003) 16:11-18.
134. MENENDEZ-ARIAS L, MARTINEZ MA, QUINONES-MATEU ME et al.: Fitness variations and their impact on the evolution of antiretroviral drug resistance. Curr. Drug. Targets Infect. Disord. (2003) 3:355-371.
135. GOODENOW MM, ROSE SL, TUTTLE DL et al.: HIV-1 fitness and macrophages. J. Leukoc. Biol. (2003) 74:657-666.
136. KALEEBU P, FRENCH N, MAHE C et al.: Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J. Infect. Dis. (2002) 185:1244-1250.
137. BALL SC, ABRAHA A, COLLINS KR et al.: Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J. Virol. (2003) 77:1021-1038.
138. QUINONES-MATEU ME, BALL SC, MAROZSAN AJ et al.: A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression J. Virol. (2000) 74:9222-9233.
139. RESCH W, ZIERMANN R, PARKIN N et al.: Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly. J. Virol. (2002) 76:8659-8666.
140. COLLINS JA, THOMPSON MG, PAINTSIL E et al.: Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J. Virol. (2004) 78:603-611.
141. MAROZSAN AJ, ARTS EJ: Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates. J. Virol. Methods (2003) 111:111-120.
142. NURPEISOV V, HURWITZ SJ, SHARMA PL: Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase. J. Clin. Microbiol. (2003) 41:3306-3311.
143. HARTMAN T: Relative replication competence of virus isolates resistant to anti-HIV compounds. Hood College: Frederick. MD, USA (2000):150.
144. WEI X, LIANG C, GOTTE M et al.: The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses. AIDS (2002) 16:2391-2398.
145. QUAN Y, GU Z, LI X et al.: Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2′-dideoxy-3′-thiacytidine by mutated M184V human immunodeficiency virus type 1. J. Virol. (1996) 70:5642-5645.
146. BACK NK, NIJHUIS M, KEULEN W et al.: Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. (1996) 15:4040-4049.
147. LARDER BA, KEMP SD, HARRIGAN PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science (1995) 269:696-699.
148. HSU M, INOUYE P, REZENDE L et al.: Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res. (1997) 25:4532-4536.
149. OUDE ESSINK BB, BACK NK, BERKHOUT B: Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase. Nucleic Acids Res. (1997) 25:3212-3217.
150. WAINBERG MA, DROSOPOULOS WC, SALOMON H et al.: Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science (1996) 271:1282-1285.
151. GOTTE M, WAINBERG MA: Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase. Drug Resist. Updat. (2000) 3:30-38.
152. DIALLO K, MARCHAND B, WEI X et al.: Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity. J. Virol. (2003) 77:8621-8632.
153. LE GRICE SF, GRUNINGER-LEITCH F: Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur. J. Biochem. (1990) 187:307-314.
154. SHARMA PL, CRUMPACKER CS: Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val. J. Virol. (1999) 73:8448-8456.
155. ST CLAIR MH, MARTIN JL, TUDOR-WILLLAMS G et al.: Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science (1991) 253:1557-1559.
156. WHITE KL, MARGOT NA, WRIN T et al.: Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme
157. QUINONES-MATEU ME, TADELE M, PARERA M et al.: Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation. J. Virol. (2002) 76:10546-10552.
158. IMAMICHI T, BERG SC, IMAMICHI H et al.: Relative replication fitness of a high-level 3′-azido-3′-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr--> Gly) at codon 69. J. Virol. (2000) 74:10958-10964.
159. KOSALARAKSA P, KAVLICK MF, MAROUN V et al.: Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay. J. Virol. (1999) 73:5356-5363.
160. MAEDA Y, VENZON DJ, MITSUYA H: Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J. Infect. Dis. (1998) 177:1207-1213.
161. GARCIA-LERMA JG, GERRISH PJ, WRIGHT AC et al.: Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1. J. Virol. (2000) 74:9339-9346.
162. GERONDELIS P, ARCHER RH, PALANIAPPAN C et al.: The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′ -end- and DNA 3′-end-directed RNase H activities. J. Virol. (1999) 73:5803-5813.
163. PAUL DA, LOGUE K, TRITCH R: Relative fitness of efavirenz (EFV, DMP 266)-resistant mutants of HIV-1. In: 39th Interscience Conference on Antimicrobial Agents in Chemotherapy. San Francisco, CA, USA (1999).
164. IGLESIAS-USSEL MD, CASADO C, YUSTE E et al.: In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. J. Gen. Virol. (2002) 83:93-101.
165. BORMAN AM, PAULOUS S, CLAVEL F: Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J. Gen. Virol. (1996) 77(Pt 3):419-426.
166. GAO Q, GU ZX, PARNIAK MA et al.: In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′ -dideoxynosine. J. Virol. (1992) 66:12-19.
167. HAVLIR D, RICHMAN D: Antiviral Drug Resistance. D Richman (Ed.), John Wiley, Chichester, UK (1996):19.
168. MENENDEZ-ARIAS L, ABRAHA A, QUINONES-MATEU ME et al.: Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent HIV-1 group M and O strains. J. Biol. Chem. (2001) 276:27470-27479.
169. HUANG W, WRIN T, GAMAMIK A et al.: XI International HIV Drug Resistance Workshop. Seville, Spain (2002)
170. DYKES C, FOX K, LLOYD A et al.: Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology (2001) 285:193-203.
171. LOFTUS TL: Relative replication competence of virus isolates resistant to anti-HIV compounds. Hood College: Frederick, MD, USA (2000).
172. TACHEDJIAN G, MELLORS JW, BAZMI H et al.: Impaired fitness of foscarnet-resistant strains of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses (1998) 14:1059-1064.
173. MYINT L, MATSUDA M, MATSUDA Z et al.: Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. (2004) 48:444-452.
174. KAPLAN AH, MICHAEL SF, WEHBIE RS et al.: Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the vital protease. Proc. Natl. Acad. Sci. USA (1994) 91:5597-5601.
175. ROSE RE, GONG YF, GREYTOK JA et al.: Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc. Natl. Acad. Sci. USA (1996) 93:1648-1653.
176. BALLY F, MARTINEZ R, PETERS S et al.: Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res. Hum. Retroviruses (2000) 16:1209-1213.
177. CARRILLO A, STEWART KD, SHAM HL et al.: In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J. Virol. (1998) 72:7532-7541.
178. MAGUIRE MF, GUINEA R, GRIFFIN P et al.: Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J. Virol. (2002) 76:7398-7406.
179. MAMMANO F, PETIT C, CLAVEL F: Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J. Virol. (1998) 72:7632-7637.
180. PRADO JG, WRIN T, BEAUCHAINE J et al.: Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS (2002) 16:1009-1017.
181. BLEIBER G, MUNOZ M, CIUFFI A et al.: Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J. Virol. (2001) 75:3291-3300.
182. CROTEAU G, DOYON L, THIBEAULT D et al.: Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. (1997) 71:1089-1096.
183. HO DD, TOYOSHIMA T, MO H et al.: Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. (1994) 68:2016-2020.
184. KAUFMANN D, MUNOZ M, BLEIBER G et al.: Virological and immunological characteristics of HIV treatment failure. AIDS (2000) 14:1767-1774.
185. MARTINEZ-PICADO J, SAVARA AV, SUTTON L et al.: Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. (1999) 73:3744-3752.
186. MARTINEZ-PICADO J, SAVARA AV, SHI L et al.: Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology (2000) 275:318-322.
187. NIJHUIS M, SCHUURMAN R, DE JONG D et al.: Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS (1999) 13:2349-2359.
188. PICCHIO GR, VALDEZ H, SABBE R et al.: Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy. J. Acquir. Immune Defic. Syndr. (2000) 25:289-295.
189. ROBINSON LH, MYERS RE, SNOWDEN BW et al.: HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays. AIDS Res. Hum. Retroviruses (2000) 16:1149-1156.
190. SCHOCK HB, GARSKY VM, KUO LC: Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J. Biol. Chem. (1996) 271:31957-31963.
191. ZENNOU V, MAMMANO F, PAULOUS S et al.: Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. (1998) 72:3300-3306.
192. PATICK AK, DURAN M, CAO Y et al.: Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. (1998) 42:2637-2644.
193. SMIDT ML, POTTS KE, TUCKER SP et al.: A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. Antimicrob. Agents Chemother. (1997) 41:515-522.
194. TUCKER SP, STIEBEL TR Jr, POTTS KE et al.: Estimate of the frequency of human immunodeficiency virus type 1 protease inhibitor resistance within unselected virus populations in vitro. Antimicrob. Agents Chemother. (1998) 42:478-480.
195. ZIERMANN R, LIMOLI K, DAS K et al.: A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J. Virol. (2000) 74:4414-4419.
196. MAMMANO F. TROUPLIN V, ZENNOU V et al.: Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug J. Virol. (2000) 74:8524-8531.
197. BOUCHER C, Rational approaches to resistance: using saquinavir. AIDS (1996) 10(Suppl. 1):S15-S19.
198. VAN OPIJNEN T, JEENINGA RE, BOERLIJST MC et al.: Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J. Virol. (2004) 78:3675-3683.
199. WEBER J, RANGEL HR, CHAKRABORTY B et al.: Role of Baseline pol Genotype in HIV-1 Fitness Evolution. J. Acquir. Immune Defic. Syndr. (2003) 33:448-460.
200. BERKHOUT B: HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. J. Biomed. Sci. (1999) 6:298-305.
201. MATSUMI S, KOSALARAKSA P, TSANG H et al.: Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants. AIDS (2003) 17:1127-1137.
202. OLIVARES I, SANCHEZ-MERINO V, MARTINEZ MA et al.: Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity. J. Virol. (1999) 73:6293-6298.
203. SHARMA PL, CRUMPACKER CS: Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J. Virol. (1997) 71:8846-8851.
204. VAN LAETHEM K, WITVROUW M, PANNECOUQUE C et al.: Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype. AIDS (2001) 15:553-561.
205. GARCIA-LERMA JG, MACINNES H, BENNETT D et al.: A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J. Virol. (2003) 77:5685-5693.
206. KAVLICK MF, WYVILL K, YARCHOAN R et al.: Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. J. Infect. Dis. (1998) 177:1506-1513.
207. IVERSEN AK, SHAFER RW, WEHRLY K et al.: Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. (1996) 70:1086-1090.
208. SCHMIT JC, VAN LAETHEM K, RUIZ L et al.: Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS (1998) 12:2007-2015.
209. TISDALE M, KEMP SD, PARRY NR et al.: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad Sci. USA (1993) 90:5653-5656.
210. AIT-KHALED M, STONE C, AMPHLETT G et al.: M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS (2002) 16:1686-1689.
211. MILLER MD, ANTON KE, MULATO AS et al.: Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J. Infect. Dis. (1999) 179:92-100.
212. WAINBERG MA, MILLER MD, QUAN Y et al.: In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir. Ther. (1999) 4:87-94.
213. MENZO S, MONACHETTI A, BALOTTA C et al.: Processivity and drug-dependence of HIV-1 protease: determinants of vital fitness in variants resistant to protease inhibitors. AIDS (2003) 17:663-671.
214. MELLORS JW RINALDO CR Jr, GUPTA P et al.: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 272:1167-1170.
215. CUNNINGHAM AL, LI S, JUAREZ J et al.: The level of HIV infection of macrophages is determined by interaction of viral and host cell genotypes. J. Leukoc. Biol. (2000) 68:311-317.
216. MICHAEL NL, NELSON JA, KEWALRAMANI VN et al.: Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 δ-32. J. Virol. (1998) 72:6040-6047.
217. MARTIN MP, DEAN M, SMITH MW et al.: Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science (1998) 282:1907-1911.
218. HEINZINGER NK, BUKINSKY MI, HAGGERTY SA et al.: The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc. Natl. Acad. Sci. USA (1994) 91:7311-7315.
219. O'BRIEN WA, NAMAZI A, KALHOR H et al.: Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J. Virol. (1994) 68:1258-1263.
220. COLLIN M, GORDON S: The kinetics of human immunodeficiency virus reverse transcription are slower in primary human macrophages than in a lymphoid cell line. Virology (1994) 200:114-120.
221. OMETTO L, DE FORNI D, PATIRI F et al.: Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness. AIDS (2002) 16:839-849.